Heart FailureNCT03105778
Point of Care Precision and Sample Comparison Study of Minicare BNP at Innsbruck Hospital - MI-BNP-CE04-AN2016
An observational study of Heart Failure, run by Philips Handheld Diagnostics at 1 site in Austria.
Trial summary
Part 1 (POC Precision): Objective : Demonstrate that the Minicare BNP (im)precision in hands of the user is within the expected range of the Minicare BNP (im)precision. Part 2 (sample comparison) Primary objective : Compare Minicare BNP values from capillary whole blood from finger stick with EDTA whole blood from… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure
- What is being tested?
- standard blood draw as part of routine and fingerprick for capillary sample
- How many people
- 100 participants
- Where
- 1 siteAustria
- Study dates
- 6 Mar 2017to 30 Nov 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patient samples from eligible patients with BNP requests, available at the test site
Who may be able to join
- 18 years or older
- patients with suspected/ diagnosed heart failure (HF)
- signed informed consent form
Who cannot join
- Patients younger than 18 years
- Patients requiring emergency treatment, those with cognitive impairment or inability to understand study information, and those unwilling or unable to provide written consent
- Patients already participated in this study
- Pregnant or breastfeeding women
- Patients with known Hepatitis B or C or HIV infection
Trial locations and contacts
1 site in 1 country.
Austria1 site, 1 recruiting
- Recruiting
Medical University of Innsbruck
Innsbruck, 6020
Johannes Mair, Prof, +43 512 504 81314, johannes.mair@i-med.ac.at
About this study
Part 1 (POC Precision):
Objective :
Demonstrate that the Minicare BNP (im)precision in hands of the user is within the expected range of the Minicare BNP (im)precision. Part 2 (sample comparison)
Primary objective :
Compare Minicare BNP values from capillary whole blood from finger stick with EDTA whole blood from venous puncture.
Secondary objective :
Compare Minicare BNP values from EDTA whole blood and plasma with Li- Heparin whole blood and plasma from venous puncture.
Read the detailed description
Study Design Part 1 (POC precision) Two levels of BNP control samples (Thermofisher) will be tested during 5 days, with 5 replicates per day by three different users to assess precision of the Minicare BNP. The two different levels need to be tested on the same analyzer by the same user. For this study, six analyzers are made available, meaning that each user will test 2 analyzers. In parallel this testing will be done at Philips to establish the expected POC (im)precision. The two (im)precision values will be compared to each other. The precision study will also be used as a proficiency study that is normally requested prior to starting enrolment. Study Design Part 2 (sample comparison)
Part 2 (Sample comparison):
This study will be a prospective European single site study with at least 100 patient samples, taken from patients presenting at the cardiology ward and coronary care unit with suspected/ diagnosed heart failure (HF) or other cardiac diseases and thus suspected elevated BNP values. The blood sample will be collected near the patient by a trained healthcare professional of the study site.
When testing capillary whole blood, the blood will be collected by a finger stick according to the local SOP's of the study site. Directly (within 1 minute) after finger stick, the blood will be transferred with capillary transfer devices, one without ant-coagulant and one containing EDTA as anti-coagulant, to the BNP cartridge that is positioned in the Minicare I-20 analyzer. Testing will be done near the bedside of the patient. Two venous whole blood tubes will be collected; one containing Li-Heparin and the other containing EDTA as anti-coagulant. The venous whole blood will be collected in the specific tubes by a venous puncture according to the local SOP's of the study site. The EDTA venous whole blood will be transferred to the Minicare BNP by using a pipet and a transfer device. The Li-Heparin and EDTA venous whole blood sample should be tested within 2 hours (keep at room temperature) after the blood is taken (preferably as soon as possible after blood taking). Li-Heparin and EDTA venous whole blood can be tested at the ward by a trained healthcare professional or in the lab by a trained lab technician. The Li-Heparin and EDTA whole blood sample will be transferred to the lab and centrifuged and tested within 2 hours after the blood is taken. The Li-Heparin and EDTA plasma should be tested within 2 hours (keep at room temperature) after the blood is taken (preferably as soon as possible after blood taking). Li- Heparin and EDTA plasma samples might be tested in the lab, dependent on local routine.
All patient samples will be tested in singleton. The time that the blood is taken and tested will be recorded for each sample. Study will continue until at least 100 patient samples covering the predefined concentration range have valid measurements. Due to experience from previous sample comparison studies (Lab2Go) the site expects the necessity to test up to 200 patients to find 100 patients within the required BNP ranges. The Minicare BNP test results will not be used as part of the patient diagnosis but only for sample comparison purposes. Testing for both Part 1 and Part 2 will be done according to the Clinical Brochure for Minicare BNP.
- Conditions
- Heart Failure
- Being tested
- standard blood draw as part of routine and fingerprick for capillary sample
- Keywords
- BNP, IVD
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
standard blood draw as part of routine and fingerprick for capillary sampleDiagnostic test
All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
What is being measured
The primary outcome is the main question the study is designed to answer.
POC precision objective
Demonstrate that the Minicare BNP (im)precision in hands of the user is within the expected range of the Minicare BNP (im)precision.
Measured: June 2017
Sample comparison objective
Compare Minicare BNP values from capillary whole blood from finger stick with EDTA whole blood from venous puncture.
Measured: June 2017
Secondary outcomes (1)
Sample comparison secondary objective
Compare Minicare BNP values from EDTA whole blood and plasma with Li- Heparin whole blood and plasma from venous puncture.
Measured: June 2017
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2017
- Study start6 Mar 2017
- Primary completion30 Nov 2017 (estimated)
- Study completion30 Nov 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Philips Handheld Diagnostics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Johannes Mair, Principal investigator, Senior Staff member
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03105778
- Sponsor's protocol ID
- HHDx-08698
- Status last verified
- Apr 2017
- First submitted
- 4 Apr 2017
- Last updated
- 18 Oct 2017
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data outcome of study may be included in publication
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Point of Care Precision and Sample Comparison Study of Minicare BNP at Innsbruck Hospital - MI-BNP-CE04-AN2016
- ClinicalTrials.gov ID
- NCT03105778
- Acronym / sponsor ID
- HHDx-08698
- Conditions
- Heart Failure
- Keywords
- BNP, IVD
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Philips Handheld DiagnosticsIndustry (pharma, biotech, devices)
- Study start
- 6 Mar 2017 (actual)
- Primary completion
- 30 Nov 2017 (estimated)
- Study completion
- 30 Nov 2017 (estimated)
- First posted
- 10 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Part 1 (POC Precision):
Objective :
Demonstrate that the Minicare BNP (im)precision in hands of the user is within the expected range of the Minicare BNP (im)precision. Part 2 (sample comparison)
Primary objective :
Compare Minicare BNP values from capillary whole blood from finger stick with EDTA whole blood from venous puncture.
Secondary objective :
Compare Minicare BNP values from EDTA whole blood and plasma with Li- Heparin whole blood and plasma from venous puncture.
Detailed description
Study Design Part 1 (POC precision) Two levels of BNP control samples (Thermofisher) will be tested during 5 days, with 5 replicates per day by three different users to assess precision of the Minicare BNP. The two different levels need to be tested on the same analyzer by the same user. For this study, six analyzers are made available, meaning that each user will test 2 analyzers. In parallel this testing will be done at Philips to establish the expected POC (im)precision. The two (im)precision values will be compared to each other. The precision study will also be used as a proficiency study that is normally requested prior to starting enrolment. Study Design Part 2 (sample comparison)
Part 2 (Sample comparison):
This study will be a prospective European single site study with at least 100 patient samples, taken from patients presenting at the cardiology ward and coronary care unit with suspected/ diagnosed heart failure (HF) or other cardiac diseases and thus suspected elevated BNP values. The blood sample will be collected near the patient by a trained healthcare professional of the study site.
When testing capillary whole blood, the blood will be collected by a finger stick according to the local SOP's of the study site. Directly (within 1 minute) after finger stick, the blood will be transferred with capillary transfer devices, one without ant-coagulant and one containing EDTA as anti-coagulant, to the BNP cartridge that is positioned in the Minicare I-20 analyzer. Testing will be done near the bedside of the patient. Two venous whole blood tubes will be collected; one containing Li-Heparin and the other containing EDTA as anti-coagulant. The venous whole blood will be collected in the specific tubes by a venous puncture according to the local SOP's of the study site. The EDTA venous whole blood will be transferred to the Minicare BNP by using a pipet and a transfer device. The Li-Heparin and EDTA venous whole blood sample should be tested within 2 hours (keep at room temperature) after the blood is taken (preferably as soon as possible after blood taking). Li-Heparin and EDTA venous whole blood can be tested at the ward by a trained healthcare professional or in the lab by a trained lab technician. The Li-Heparin and EDTA whole blood sample will be transferred to the lab and centrifuged and tested within 2 hours after the blood is taken. The Li-Heparin and EDTA plasma should be tested within 2 hours (keep at room temperature) after the blood is taken (preferably as soon as possible after blood taking). Li- Heparin and EDTA plasma samples might be tested in the lab, dependent on local routine.
All patient samples will be tested in singleton. The time that the blood is taken and tested will be recorded for each sample. Study will continue until at least 100 patient samples covering the predefined concentration range have valid measurements. Due to experience from previous sample comparison studies (Lab2Go) the site expects the necessity to test up to 200 patients to find 100 patients within the required BNP ranges. The Minicare BNP test results will not be used as part of the patient diagnosis but only for sample comparison purposes. Testing for both Part 1 and Part 2 will be done according to the Clinical Brochure for Minicare BNP.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patient samples from eligible patients with BNP requests, available at the test site
Key inclusion criteria (3 listed)
- 18 years or older
- patients with suspected/ diagnosed heart failure (HF)
- signed informed consent form
Key exclusion criteria (5 listed)
- Patients younger than 18 years
- Patients requiring emergency treatment, those with cognitive impairment or inability to understand study information, and those unwilling or unable to provide written consent
- Patients already participated in this study
- Pregnant or breastfeeding women
- Patients with known Hepatitis B or C or HIV infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| standard blood draw as part of routine and fingerprick for capillary sampleAll blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study. | Diagnostic test | – |
Primary outcome
POC precision objective
Time frame: June 2017
Demonstrate that the Minicare BNP (im)precision in hands of the user is within the expected range of the Minicare BNP (im)precision.
Sample comparison objective
Time frame: June 2017
Compare Minicare BNP values from capillary whole blood from finger stick with EDTA whole blood from venous puncture.
1 secondary outcome
Sample comparison secondary objective
Time frame: June 2017
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2017.
- Individual participant dataSharing planned: Undecided. Data outcome of study may be included in publication
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Johannes Mair principal investigator
Senior Staff member
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure, run by Philips Handheld Diagnostics at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Diederick Keizer (+31 6 11386644, diederick.keizer@philips.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
POC precision objective (time frame: June 2017). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2017.